SAN DIEGO, CA, February 15, 2014 /24-7PressRelease/ -- Larvol Sigma is the first free clinical trial and pipeline intelligence platform. In addition to faster, easier access to ClinicalTrials.gov and EudraCT, the platform provides advanced analytics tailored to meet the specific needs of the pharmaceutical and biotech industries. With a database containing over 5,000 drugs as well as more than 150,000 individual drug trials across all major indications, Larvol Sigma is a comprehensive free resource for researchers and industry professionals.
"From trial registries and publications to financial disclosure reports, large amounts of data about KOLs falls within the public domain," said company President, Bruno Larvol "but there are substantial challenges in extracting and organizing the data in a meaningful way. We have brought together data mining and relationship visualization tools to allow users to easily identify and prioritize KOLs according to their work with more than 4,000 indications, products and companies." To preview Larvol Sigma, please visit http://www.larvolsigma.com.
For more information regarding how The Larvol Group can assist your organization, please visit our booth at the conference. If you would like to schedule a meeting with Bruno Larvol or Vice-president Laura Farmer during the event, please contact Natalie Gulley at email@example.com or (415) 874-3310.
About The Larvol Group, LLC: Founded in 2004, The Larvol Group (www.larvol.com) is a San Francisco-based competitive intelligence company which provides innovative business intelligence services for the pharmaceutical industry. Their customized Market Intelligence Reports track relevant news, clinical trials and developments in the competitive landscape of a given indication. Drawing on the knowledge of over 100 professionals, The Larvol Group has expertise in all major therapeutic areas, including oncology, cardiovascular, metabolic diseases, CNS, immunology, women's health and pain management. Their diverse portfolio of clients includes top pharmaceutical companies and small to midsized biotech firms.
# # #Read more Press Releases from Natalie Gulley: